TY  - JOUR
A1  - Liebers, Nora
A1  - Duell, Johannes
A1  - Fitzgerald, Donnacha
A1  - Kerkhoff, Andrea
A1  - Noerenberg, Daniel
A1  - Kaebisch, Eva
A1  - Acker, Fabian
A1  - Fuhrmann, Stephan
A1  - Leng, Corinna
A1  - Welslau, Manfred
A1  - Chemnitz, Jens
A1  - Middeke, Jan-Moritz
A1  - Weber, Thomas
A1  - Holtick, Udo
A1  - Trappe, Ralf
A1  - Pfannes, Roald
A1  - Liersch, Ruediger
A1  - Spoer, Christian
A1  - Fuxius, Stefan
A1  - Gebauer, Niklas
A1  - Caillé, Léandra
A1  - Geer, Thomas
A1  - Koenecke, Christian
A1  - Keller, Ulrich
A1  - Claus, Rainer
A1  - Mougiakakos, Dimitrios
A1  - Mayer, Stephanie
A1  - Huettmann, Andreas
A1  - Pott, Christiane
A1  - Trummer, Arne
A1  - Wulf, Gerald
A1  - Brunnberg, Uta
A1  - Bullinger, Lars
A1  - Hess, Georg
A1  - Mueller-Tidow, Carsten
A1  - Glass, Bertram
A1  - Lenz, Georg
A1  - Dreger, Peter
A1  - Dietrich, Sascha
T1  - Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
JF  - Blood Advances
N2  - The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients.
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-369173
VL  - 5
ER  - 
TY  - JOUR
A1  - Lux, Michael P.
A1  - Schneeweiss, Andreas
A1  - Hartkopf, Andreas D.
A1  - Müller, Volkmar
A1  - Janni, Wolfgang
A1  - Belleville, Erik
A1  - Stickeler, Elmar
A1  - Thill, Marc
A1  - Fasching, Peter A.
A1  - Kolberg, Hans-Christian
A1  - Untch, Michael
A1  - Harbeck, Nadia
A1  - Wöckel, Achim
A1  - Thomssen, Christoph
A1  - Schulmeyer, Carla E.
A1  - Welslau, Manfred
A1  - Overkamp, Friedrich
A1  - Schütz, Florian
A1  - Lüftner, Diana
A1  - Ditsch, Nina
T1  - Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients
JF  - Geburtshilfe und Frauenheilkunde
N2  - In recent years, significant progress has been made in new therapeutic approaches to breast cancer, particularly in patients with HER2-positive and HER2-negative/hormone receptor-positive (HR+) breast cancer. In the case of HER2-positive tumours, these approaches have included, in particular, treatment with pertuzumab, T-DM1, neratinib and, soon, also tucatinib and trastuzumab deruxtecan (neither of which has yet been authorised in Europe). In patients with HER2−/HR+ breast cancer, CDK4/6 inhibitors and the PIK3CA inhibitor alpelisib are of particular importance. Further novel therapies, such as Akt kinase inhibitors and oral SERDs (selective estrogen receptor down regulators), are already being investigated in ongoing clinical trials. These therapeutic agents are not only being introduced into curative, (neo-)adjuvant therapeutic settings for HER2-positive tumours; a first favourable study on abemaciclib as an adjuvant therapy has now also been published. In patients with triple-negative breast cancer, after many years of negative study results with the Trop-2 antibody drug conjugate (ADC) sacituzumab govitecan, a randomised study has been published that may represent a significant therapeutic advance. This review describes the latest developments in breast cancer subsequent to the ESMO Congress 2020.
KW  - early breast cancer
KW  - therapy
KW  - prognosis
KW  - immune therapy
KW  - digital medicine
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-369989
VL  - 81
ER  -